CANDICE CASE: Open Payments
NPI 1649042987 · OWINGS MILLS, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,294 in 63 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $911 · 2025 $1,294
Food & beverage: $1,294
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 16 | $322 |
| Verona Pharma, Inc. | 13 | $182 |
| AstraZeneca Pharmaceuticals LP | 8 | $180 |
| GENZYME CORPORATION | 3 | $82 |
| Axsome Therapeutics, Inc. | 3 | $81 |
| Grifols USA, LLC | 3 | $67 |
| HARMONY BIOSCIENCES LLC | 3 | $66 |
| Electromed, Inc. | 2 | $58 |
| Lilly USA, LLC | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $53 |
Products named: NUCALA, Ohtuvayre, TRELEGY ELLIPTA, DUPIXENT, AIRSUPRA, Sunosi, FASENRA, Prolastin-C Liquid.
Industry payments across MD — which companies pay providers there.
